Incannex appoints Douglas B. Kirsch to IHL-42X Clinical Advisory Board.

Incannex Healthcare has appointed Douglas B. Kirsch, M.D., FAAN, FAASM to its IHL-42X Obstructive Sleep Apnea Clinical Advisory Board. Kirsch has extensive clinical experience and leadership in the sleep medicine community, and his addition strengthens the advisory board's expertise as IHL-42X advances through late-stage development.

Incannex Healthcare Inc. (Nasdaq: IXHL), a clinical-stage biopharmaceutical company advancing combination drug therapies for high-impact indications, has appointed Douglas B. Kirsch, M.D., FAAN, FAASM, to its IHL-42X Obstructive Sleep Apnea (OSA) Clinical Advisory Board. Dr. Kirsch's extensive clinical experience and leadership within the sleep medicine community will be instrumental in advancing the IHL-42X program through late-stage development [1].

Dr. Kirsch is a recognized authority in sleep medicine with a long-standing track record of clinical, academic, and organizational leadership. He currently serves as Medical Director of Atrium Health Sleep Medicine, overseeing clinical sleep medicine services across a large, multi-state hospital system while maintaining an active clinical practice. He is also a Clinical Professor in the Department of Neurology at the Wake Forest School of Medicine and has previously held faculty appointments at the University of Michigan Medical School and Harvard Medical School. Dr. Kirsch's leadership roles include serving as President of the American Academy of Sleep Medicine (AASM) from 2018 to 2019 and playing a leading role in national education efforts, including as Program Chair for the SLEEP Meeting (2012–2014) and Chair of the AASM Sleep Medicine Trends course (2023–2025).

His current interests focus on emerging technologies in sleep medicine and demonstrating the value of sleep care across healthcare systems. Dr. Kirsch joins recently announced advisors Scott A. Sands, Ph.D., Ali Azarbarzin, Ph.D., Nancy Collop, M.D., and Lora J. McGill, M.D., FAAN, in supporting the advancement of IHL-42X, an oral fixed-dose combination therapy designed to address obstructive sleep apnea by targeting the physiological mechanisms of intermittent hypoxia and hypercapnia.

Incannex expects to report topline Phase 2 data from its U.S. RePOSA study in July 2025, with Phase 3 initiation targeted for later in the year. The Company is pleased to have achieved database lock for the RePOSA Phase 2 trial of IHL-42X, marking a major milestone in the development of IHL-42X and confirming the completion of clinical data collection [2].

References:
[1] https://finance.yahoo.com/news/incannex-healthcare-expands-clinical-advisory-113000458.html
[2] https://www.globenewswire.com/news-release/2025/06/18/3101356/0/en/Incannex-achieves-key-milestone-with-database-lock-for-RePOSA-Phase-2-trial-of-IHL-42X.html